Exicure, Inc. Common Stock
XCUR
XCUR: Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.
moreShow XCUR Financials
Recent trades of XCUR by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by XCUR's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use Jan. 19, 2021
-
Patent Title: Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use Nov. 17, 2020
-
Patent Title: Anti-tnf compounds Sep. 01, 2020
-
Patent Title: Nucleic acid nanostructures with core motifs Jul. 07, 2020
-
Patent Title: Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications Oct. 08, 2019
-
Patent Title: Anti-tnf compounds Feb. 19, 2019
Federal grants, loans, and purchases
Followers on XCUR's company Twitter account
Number of mentions of XCUR in WallStreetBets Daily Discussion
Recent insights relating to XCUR
Recent picks made for XCUR stock on CNBC
ETFs with the largest estimated holdings in XCUR
Flights by private jets registered to XCUR